- CareDx (CDNA, Financial) grants inducement stock awards to newly appointed Chief Product Officer, Jennifer Foley.
- The compensation package includes 36,231 RSUs and PSUs targeting up to 31,056 shares.
- RSUs and PSUs follow structured vesting schedules over multiple years, aligned with performance goals.
CareDx, Inc. (CDNA), a leader in precision medicine solutions for transplant patients, recently announced inducement stock awards to Jennifer Foley, who has been appointed as the new Chief Product Officer. On April 7, 2025, the company granted Foley a compensation package comprising 36,231 restricted stock units (RSUs) under the 2016 Inducement Equity Incentive Plan.
Additionally, Foley received performance-based stock units (PSUs) with 15,528 shares at target levels that can increase to 31,056 shares at maximum performance levels according to the 2019 Inducement Equity Incentive Plan. These plans were approved under Nasdaq Listing Rule 5635(c)(4).
The RSUs are set to vest over a period of four years, with 25% vesting after the first year and the remaining 1/16th vesting quarterly thereafter, contingent upon her continued employment. The PSUs have a two-year performance period with an extra year for time-based vesting. Fifty percent of the PSUs are eligible to vest by February 1, 2026, dependent on meeting certain performance goals, and the remaining fifty percent will vest in equal installments on February 1, 2027, and 2028.
CareDx focuses on discovering and commercializing healthcare solutions tailored for transplant patients and caregivers, providing a comprehensive range of services along the pre- and post-transplant patient journey.
